Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 3/2001

01-03-2001 | Current Opinion

Neuroprotection for Ischaemic Stroke

An Unattainable Goal?

Authors: Dr David S. Liebeskind, Scott E. Kasner

Published in: CNS Drugs | Issue 3/2001

Login to get access

Abstract

Neuroprotective therapies for acute ischaemic stroke have yet to be realised despite the determined efforts of basic science and clinical investigators. Progressive elucidation of the complex pathophysiology involved in the ischaemic cascade has led to the development of numerous candidate interventions. Preliminary efficacy in animal models has repeatedly resulted in frustration after extensive clinical testing. Failure in the translation of results from animal models to humans implicates potential limitations of the current drug development process. Reflection on prior studies suggests possible flaws at several stages. Incorporation of standardised guidelines for preclinical testing of putative neuroprotective therapies and modification of clinical trial design, methodology and reporting may improve chances for success. The future of neuroprotection for stroke remains bright in spite of previous disappointments.
Literature
1.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333(24): 1581–7CrossRef
2.
The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke 1997; 28(8): 1530–40CrossRef
3.
O’Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33(1): 9–14CrossRefPubMed
4.
Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53(7 Suppl. 4): S3–14PubMed
5.
De Graba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurol Clin 2000; 18(2): 475–93CrossRef
6.
Muir KW, Grosset DG. Neuroprotection for acute stroke: making clinical trials work. Stroke 1999; 30(1): 180–2CrossRefPubMed
7.
8.
9.
Wardlaw JM, Warlow CP, Sandercock PA, et al. Neuroprotection disappointment yet aGAIN. Lancet 2000; 356(9229): 597CrossRefPubMed
10.
De Keyser J, Suiter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 1999; 22(12): 535–40CrossRefPubMed
11.
Emerich DF. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 2000; 23(6): 245–6CrossRefPubMed
12.
Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls? Lancet 2000; 355(9219): 1925–6CrossRefPubMed
13.
Lutsep HL, Clark WM. Neuroprotection in acute ischaemic stroke: Current status and future potential. Drugs R D 1999; 1(1): 3–8CrossRefPubMed
14.
Frerichs KU. Neuroprotective strategies in nature: novel clues for the treatment of stroke and trauma. Acta Neurochir Suppl 1999; 73: 57–61
15.
Heiss WD, Thiel A, Grond M, et al. Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999; 30(7): 1486–9CrossRefPubMed
16.
Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000; 355(9219): 1949–54CrossRefPubMed
17.
The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators. Phase II studies of the glycine antagonist GV150526 in acute stroke: the North American experience. Stroke 2000; 31(2): 358–65CrossRef
18.
Di Fabio R, Cugola A, Donati D, et al. Identification and pharmacological characterisation of GV150526, a novel glycine antagonist as a potent neuroprotective agent. Drugs Future 1998; 23: 62–9
19.
Small DL, Morley P, Buchan AM. Biology of ischemic cerebral cell death. Prog Cardiovasc Dis 1999; 42(3): 185–207CrossRefPubMed
20.
Davis M, Barer D. Neuroprotection in acute ischaemic stroke. II: Clinical potential. Vasc Med 1999; 4(3): 149–63PubMed
21.
Morgenstern LB, Pettigrew LC. Brain protection: human data and potential new therapies. New Horiz 1997; 5(4): 397–405PubMed
22.
Dorman PJ, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs 1996; 5(6): 457–74CrossRef
23.
24.
Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36(4): 557–65CrossRefPubMed
25.
Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26(3): 503–13CrossRefPubMed
26.
Zornow MH, Prough DS. Neuroprotective properties of calcium-channel blockers. New Horiz 1996; 4(1): 107–14PubMed
27.
28.
29.
El Kossi MM, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000; 31(8): 1889–92CrossRefPubMed
30.
Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19(8): 819–34CrossRefPubMed
31.
DeGraba TJ. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology 1998; 51(3 Suppl. 3): S62–8CrossRefPubMed
32.
Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137(2): 69–78CrossRefPubMed
33.
Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999; 399(6738 Suppl.): A7–14CrossRefPubMed
34.
Robertson GS, Crocker SJ, Nicholson DW, et al. Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000; 10(2): 283–92CrossRefPubMed
35.
Liebeskind DS, Kidwell CS, Saver JL. Meta-analysis of acute stroke trials employing neuroprotective agents [abstract]. Neurology 1998; 50(S4): A346
36.
Muir KW, Hamilton SJ, Lunnon MW, et al. Safety and tolerability of 619C89 after acute stroke. Cerebrovasc Dis 1998; 8(1): 31–7CrossRefPubMed
37.
Albers GW, Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 1995; 26(2): 254–8CrossRefPubMed
38.
Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31(2): 347–54CrossRefPubMed
39.
Dyker AG, Edwards KR, Fayad PB, et al. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke 1999; 30(10): 2038–42CrossRefPubMed
40.
Dyker AG, Lees KR. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 1999; 30(9): 1796–801CrossRefPubMed
41.
The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23(1): 3–8CrossRef
42.
Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30(12): 2592–7CrossRefPubMed
43.
Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 1996; 27(1): 76–81CrossRefPubMed
44.
Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole ischemic Stroke Study Group. Stroke 1997; 28(12): 2338–46CrossRefPubMed
45.
Diener HC. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 1998; 8(3): 172–81CrossRefPubMed
46.
Jonas S. Prophylactic pharmacologic neuroprotection against focal cerebral ischemia. Ann N Y Acad Sci 1995; 765: 21–5; discussion 26-7CrossRefPubMed
47.
The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Third Report of an Ad Hoc Consensus Group Meeting. Cerebrovasc Dis 1998; 8(1): 59–72CrossRef
48.
Dyker AG, Lees KR. Duration of neuroprotective treatment for ischemic stroke. Stroke 1998; 29(2): 535–42CrossRefPubMed
49.
Fisher M, Jonas S, Sacco RL, et al. Prophylactic neuroprotection for cerebral ischemia. Stroke 1994; 25(5): 1075–80CrossRefPubMed
50.
Schmid-Elsaesser R, Hungerhuber E, Zausinger S, et al. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke 1999; 30(9): 1891–9CrossRefPubMed
51.
Lindsberg PJ, Roine RO, Tatlisumak T, et al. The future of stroke treatment. Neurol Clin 2000; 18(2): 495–510CrossRefPubMed
52.
Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30(12): 2752–8CrossRef
53.
Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276(8): 637–9CrossRefPubMed
54.
Gong X, Sucher NJ. Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Trends Pharmacol Sci 1999; 20(5): 191–6CrossRefPubMed
55.
Green PS, Simpkins JW Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000; 18(4–5): 347–58CrossRefPubMed
56.
Hum PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 2000; 20(4): 631–52
57.
Dorman PJ, Sandercock PA. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 1996; 27(9): 1507–15CrossRefPubMed
58.
Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci 1995; 16(4): 123–8CrossRefPubMed
59.
Saver JL, Johnston KC, Homer D, et al. The RANTTAS Investigators: infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. Stroke 1999; 30(2): 293–8CrossRefPubMed
60.
Missler U, Wiesmann M, Friedrich C, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28(10): 1956–60CrossRefPubMed
61.
62.
Warach S, Pettigrew LC, Dashe JF, et al. The effect of citicoline on lesion volume in acute stroke: a multicenter, double-blind placebo-controlled trial [abstract]. Stroke 1999; 30: 243
63.
Liebeskind DS, Kidwell CS, Saver JL. Quality of acute ischemic stroke trials: time trends and effect of funding source [abstract]. Neurology 1999; 52(2 Suppl.): A556
64.
Liebeskind DS, Kidwell CS, Saver JL. Empiric evidence of publication bias affecting acute stroke clinical trials [abstract]. Stroke 1999; 30(1): 268
65.
Sandercock P. What questions can large, simple trials answer? Cerebrovasc Dis 1998; 8 Suppl 2: 30–6CrossRef
66.
Dennis M, Wardlaw J, Sandercock P, et al. Families of trials: the answers to all our questions? Cerebrovasc Dis 1999; 9(6): 305–13CrossRefPubMed
Metadata
Title
Neuroprotection for Ischaemic Stroke
An Unattainable Goal?
Authors
Dr David S. Liebeskind
Scott E. Kasner
Publication date
01-03-2001
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 3/2001
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115030-00001

Other articles of this Issue 3/2001

CNS Drugs 3/2001 Go to the issue

Therapy in Practice

Kleptomania

Review Article

Occupational Exposure to Volatile Anaesthetics

Adis Drug Evaluation

Tianeptine

Therapy in Practice

Psychotic and Mood Disorders Associated with the Perimenopausal Period

Review Article

Visual Field Defects with Vigabatrin